Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results

被引：0

作者：

Gutierrez, Martin

Spreafico, Anna

Wang, Ding

Golan, Talia

Renouf, Daniel

Voskoboynik, Mark

Chatterjee, Manash Shankar

Kapadia, Kishan J.

Liu, Qi

Kovvali, Gopala

Suttner, Leah

Pang, Ling

Chen, Mei

Tolcher, Anthony W.

机构：

[1] Hackensack Univ Med Ctr, Hackensack, NJ USA

[2] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Merck Co Inc, Kenilworth, NJ USA

[4] Henry Ford Hosp, Detroit, MI USA

[5] Tel Aviv Univ, Sheba Med Ctr, Ramat Gan, Israel

[6] BC Cancer, Vancouver, BC, Canada

[7] Univ British Columbia, Vancouver, BC, Canada

[8] Monash Univ, Cent Clin Sch, Alfred Hlth, Melbourne, Vic, Australia

[9] Merck Co Inc, Kenilworth, NJ USA

[10] South Texas Accelerated Res Therapeut, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2505

引用

页数：1

共 50 条

[41] Phase 1 study of the anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482+pembrolizumab (pembro) plus paclitaxel for previously untreated advanced triple negative breast cancer (TNBC). [J].

Rojas, Carlos ;

Victoria, Ivan ;

Ahn, Jin-Hee ;

Park, John J. ;

Reyes, Felipe ;

Curigliano, Giuseppe ;

Edmondson, Mackenzie ;

Myer, Nicole ;

Bear, Adham Sean ;

Chen, Mei ;

Spreafico, Anna .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :e13135-e13135

[42] First-in-human phase 1 clinical trial of ZM008, a monoclonal IgG1 targeting LLT1, monotherapy and in combination with pembrolizumab in advanced solid tumors [J].

Ghosh, Maloy ;

Tiwari, Anurag ;

Dubey, Ashvini Kumar ;

Bhattacharjee, Sanghamitra ;

Manjunath, Yogendra ;

Kashipathi, Shalini ;

Krishna, Subith ;

Mandal, Tirtha ;

Madhusudhan, M. S. ;

Rodrigues, Golding .

CANCER RESEARCH, 2024, 84 (06)

[43] A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor EIK1003 as monotherapy and in combination in patients with advanced solid tumors Free [J].

Falchook, Gerald ;

Rasco, Drew ;

Zhang, Jian ;

Li, Yongsheng ;

Zhu, Jianqing ;

Sohn, Joohyuk ;

Teng, Christina ;

Doger, Bernard ;

Hsieh, Chih-Yi ;

Taromino, Caroline ;

Zhang, Yawei ;

Chen, Viola J. ;

Sonpavde, Guru .

CANCER RESEARCH, 2025, 85 (08)

[44] Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE). [J].

Papadopoulos, Kyriakos P. ;

Lakhani, Nehal J. ;

Yap, Timothy A. ;

Naumovski, Allison L. ;

Brown, Karen S. ;

Umiker, Ben ;

McGrath, Lara ;

Zhang, Weidong ;

Stack, Edward ;

Riley, Gosia ;

Mota, Nancy ;

Tasillo, Christina ;

Laken, Haley ;

Trehu, Elizabeth G. ;

Baeck, Johan .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[45] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors [J].

Infante, Jeffrey R. ;

Mendelson, David S. ;

Burris, Howard A., III ;

Bendell, Johanna C. ;

Tolcher, Anthony W. ;

Gordon, Michael S. ;

Gillenwater, Heidi H. ;

Arastu-Kapur, Shirin ;

Wong, Hansen L. ;

Papadopoulos, Kyriakos P. .

INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) :216-224

[46] Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors [J].

Rodriguez-Rivera, Ildefonso Ismael ;

Moser, Justin C. ;

Opyrchal, Mateusz ;

Curti, Brendan ;

Bilen, Mehmet A. ;

Park, Saero ;

Bruno, Marissa ;

Windt, Paul ;

Subramanian, Kulandayan K. ;

Chopra, Sameer S. ;

Isaacs, Randi .

CANCER RESEARCH, 2023, 83 (08)

[47] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors [J].

Jeffrey R. Infante ;

David S. Mendelson ;

Howard A. Burris ;

Johanna C. Bendell ;

Anthony W. Tolcher ;

Michael S. Gordon ;

Heidi H. Gillenwater ;

Shirin Arastu-Kapur ;

Hansen L. Wong ;

Kyriakos P. Papadopoulos .

Investigational New Drugs, 2016, 34 :216-224

[48] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors [J].

Daud, Adil I. ;

Ashworth, Michelle T. ;

Strosberg, Jonathan ;

Goldman, Jonathan W. ;

Mendelson, David ;

Springett, Gregory ;

Venook, Alan P. ;

Loechner, Sabine ;

Rosen, Lee S. ;

Shanahan, Frances ;

Parry, David ;

Shumway, Stuart ;

Grabowsky, Jennifer A. ;

Freshwater, Tomoko ;

Sorge, Christopher ;

Kang, Soonmo Peter ;

Isaacs, Randi ;

Munster, Pamela N. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1060-+

[49] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors [J].

Eskens, F. ;

Opdam, F. ;

Gort, E. ;

Gelderblom, H. ;

Prestegarden, L. ;

Pico-Navarro, C. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S758-S758

[50] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors [J].

Bendell, Johanna C. ;

Patel, Manish R. ;

Moore, Kathleen N. ;

Chua, Cynthia C. ;

Arkenau, Hendrik-Tobias ;

Dukart, Gary ;

Harrow, Kim ;

Liang, Chris .

ONCOLOGIST, 2019, 24 (04) :455-E121

← 1 2 3 4 5 →